MedTrace Logo

Random-start Ovarian Stimulation in Egg-donors (ROSE)

NCT02821819 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-08-19

Study results available
· View outcomes & findings →

Summary

The purpose of this prospective single-center study is to evaluate the laboratory outcome after random start ovarian stimulation in oocyte donors. The study will be performed in egg-donors but this type of treatment has the potential to be implemented in general infertility population.

Conditions

Interventions

OTHER

Random start ovarian stimulation

Egg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle.

DRUG

Gonadotrophins

Urinary FSH 150-225 IU/d

DRUG

GnRH antagonist

Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation

DRUG

GnRH agonist

GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.

Sponsors & Collaborators

  • Instituto Bernabeu

    lead OTHER

Principal Investigators

  • Juan C Castillo, Md. PhD. · Instituto Bernabeu

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-10
Primary Completion
2018-01-12
Completion
2018-01-12

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02821819 on ClinicalTrials.gov